p38 inhibition ameliorates skin and skull abnormalities in Fgfr2 Beare-Stevenson mice

Journal of Clinical Investigation

Volumn 122, Issue 6, 2012, Pages 2153-2164

  Wang, Yingli ^a   Zhou, Xueyan ^a   Oberoi, Kurun ^a,b   Phelps, Robert ^a   Couwenhoven, Ross ^b,c   Sun, Miao ^b,d   Rezza, Amélie ^a   Holmes, Greg ^a   Percival, Christopher J ^e   Friedenthal, Jenna ^a   Krejci, Pavel ^f,g,h   Richtsmeier, Joan T ^b,e   Huso, David L ^b   Rendl, Michael ^a   Jabs, Ethylin Wang ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

^d INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^e PENNSYLVANIA STATE UNIVERSITY   (United States)

^f CEDARS SINAI MEDICAL CENTER   (United States)

^g MASARYK UNIVERSITY   (Czech Republic)

^h Department of Cytokinetics   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; FIBROBLAST GROWTH FACTOR RECEPTOR 2; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN;

ACANTHOSIS NIGRICANS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEARE STEVENSON CUTIS GYRATA SYNDROME; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; CRANIOFACIAL SYNOSTOSIS; DISEASE MODEL; EMBRYO; EPIDERMIS HYPERPLASIA; GENE MUTATION; MOUSE; NONHUMAN; PHOSPHORYLATION; PLEIOTROPY; PRIORITY JOURNAL; SKULL DEVELOPMENT; SKULL MALFORMATION; WNT SIGNALING PATHWAY;

ABNORMALITIES, MULTIPLE; ACANTHOSIS NIGRICANS; AMINO ACID SUBSTITUTION; ANIMALS; CRANIOSYNOSTOSES; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, TRANSGENIC; MUTATION, MISSENSE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; SKIN ABNORMALITIES; SKULL; SYNDROME;

EID: 84861801246     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI62644     Document Type: Article

References (85)

1. Beare JM, Dodge JA, Nevin NC. Cutis gyratum, acanthosis nigricans and other congenital anomalies. A new syndrome. Br J Dermatol. 1969;81(4):241-247.
2. Stevenson RE, Ferlauto JG, Taylor HA. Cutis gyratum and acanthosis nigricans associated with other anomalies: A distinctive syndrome. J Pediatr. 1978;92(6):950-952.
3. Hall BD, Cadle RG, Golabi M, Morris CA, Cohen MM Jr. Beare-Stevenson cutis gyrata syndrome. Am J Med Genet. 1992;44(1):82-89.
4. Vargas RA, et al. Beare-Stevenson syndrome: Two South American patients with FGFR2 analysis. Am J Med Genet A. 2003;121A(1):41-46. (Pubitemid 37059340)
5. Stuart CA, Pate CJ, Peters EJ. Prevalence of acanthosis nigricans in an unselected population. Am J Med. 1989;87(3):269-272. (Pubitemid 19234278)
6. Rogers DL. Acanthosis nigricans. Semin Dermatol. 1991;10(3):160-163.
7. Schwartz RA. Acanthosis nigricans. J Am Acad Dermatol. 1994;31(1):1-19.
8. Brown J, Winkelmann RK. Acanthosis nigricans: A study of 90 cases. Medicine. 1968;47(1):33-51.
9. Dunaif A, Green G, Phelps RG, Lewohl M, Futterwiet W, Lewy L. Acanthosis nigricans, insulin action and hyperandrogenism: Clinical, histological and biochemical findings. J Clin Endocrin Metab. 1991;73(3):590-595. (Pubitemid 21921913)
10. Cohen MM, Maclean RE, eds. Craniosynostosis: Diagnosis, Evaluation, And Management. New York, New York, USA; Oxford University Press; 2000.
11. Cohen MM Jr. The new bone biology: Pathologic, molecular, and clinical correlates. Am J Med Genet A. 2006;140(23):2646-2706.
12. Becker DB, Petersen JD, Kane AA, Cradock MM, Pilgram TK, Marsh JL. Speech, cognitive, and behavioral outcomes in nonsyndromic craniosynostosis. Plast Reconstr Surg. 2005;116(2):400-407. (Pubitemid 41077186)
13. Boulet SL, Rasmussen SA, Honein MA. A population-based study of craniosynostosis in metropolitan Atlanta, 1989-2003. Am J Med Genet A. 2008;146A(8):984-991.
14. Przylepa KA, et al. Fibroblast growth factor receptor 2 mutations in Beare-Stevenson cutis gyrata syndrome. Nat Genet. 1996;13(4):492-494. (Pubitemid 26259929)
15. Hsu TY, Chang SY, Wang TJ, Ou CY, Chen ZH, Hsu PH. Prenatal sonographic appearance of Beare Stevenson cutis gyrata syndrome: Two- and three-dimensional ultrasonographic findings. Prenat Diagn. 2001;21(8):665-667. (Pubitemid 32843925)
16. Akai T, Iizuka H, Kishibe M, Kawakami S, Kobayashi A, Ozawa T. A case of Beare-Stevenson cutis gyrata syndrome confirmed by mutation analysis of the fibroblast growth factor receptor 2 gene. Pediatr Neurosurg. 2002;37(2):97-99. (Pubitemid 34977959)
17. Wang TJ, Huang CB, Tsai FJ, Wu JY, Lai RB, Hsiao M. Mutation in the FGFR2 gene in a Taiwanese patient with Beare-Stevenson cutis gyrata syndrome. Clin Genet. 2002;61(3):218-221. (Pubitemid 36372636)
18. Eun SH, et al. The first Korean case of Beare-Stevenson syndrome with a Tyr375Cys mutation in the fibroblast growth factor receptor 2 gene. J Korean Med Sci. 2007;22(2):352-356.
19. Fonseca R, Costa-Lima MA, Cosentino V, Orioli IM. Second case of Beare-Stevenson syndrome with an FGFR2 Ser372Cys mutation. Am J Med Genet A. 2008;146A(5):658-660.
20. Ornitz DM, Marie PJ. FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes Dev. 2002;16(12):1446-1465. (Pubitemid 34686327)
21. Fuchs E. Skin stem cells: rising to the surface. J Cell Biol. 2008;180(2):273-284. (Pubitemid 351185914)
22. Hajihosseini MK. Fibroblast growth factor signaling in cranial suture development and pathogenesis. Front Oral Biol. 2008;12:160-177.
23. Katoh M. FGFR2 abnormalities underlie a spectrum of bone, skin, and cancer pathologies. J Invest Dermatol. 2009;129(8):1861-1867.
24. Fuchs E, Raghavan S. Getting under the skin of epidermal morphogenesis. Nat Rev Genet. 2002;3(3):199-209. (Pubitemid 34506588)
25. Opperman LA. Cranial sutures as intramembranous bone growth sites. Dev Dyn. 2000;219(4):472-485.
26. Werner S, et al. The function of KGF in morphogenesis of epithelium and reepithelialization of wounds. Science. 1994;266(5186):819-822. (Pubitemid 24359294)
27. LaRochelle WJ, et al. Specific receptor detection by a functional keratinocyte growth factor-immunoglobulin chimera. J Cell Biol. 1995;129(2):357-366.
28. Petiot A, Conti FJ, Grose R, Revest JM, Hodivala-Dilke KM, Dickson C. A crucial role for Fgfr2-IIIb signalling in epidermal development and hair follicle patterning. Development. 2003;130(22):5493-5501. (Pubitemid 37484016)
29. Steiling H, Werner S. Fibroblast growth factors: key players in epithelial morphogenesis, repair and cytoprotection. Curr Opin Biotechnol. 2003;14(5):533-537. (Pubitemid 37298040)
30. Grose R, et al. The role of fibroblast growth factor receptor 2b in skin homeostasis and cancer development. EMBO J. 2007;26(5):1268-1278. (Pubitemid 46398706)
31. Yang J, et al. Fibroblast growth factor receptors 1 and 2 in keratinocytes control the epidermal barrier and cutaneous homeostasis. J Cell Biol. 2010;188(6):935-952.
32. Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 2005;16(2):139-149. (Pubitemid 40616112)
33. Marie PJ, Kaabeche K, Guenou H. Roles of FGFR2 and twist in human craniosynostosis: Insights from genetic mutations in cranial osteoblasts. Front Oral Biol. 2008;12:144-159.
34. Melville H, Wang Y, Taub PJ, Jabs EW. Genetic basis of potential therapeutic strategies for craniosynostosis. Am J Med Genet A. 2010;152A(12):3007-3015.
35. Miraoui H, Marie PJ. Fibroblast growth factor receptor signaling crosstalk in skeletogenesis. Sci Signal. 2010;3(146):re9.
36. Mailleux AA, et al. Role of FGF10/FGFR2b signaling during mammary gland development in the mouse embryo. Development. 2002;129(1):53-60. (Pubitemid 34863775)
37. Eswarakumar VP, Monsonego-Ornan E, Pines M, Antonopoulou I, Morriss-Kay GM, Lonai P. The IIIc alternative of Fgfr2 is a positive regulator of bone formation. Development. 2002;129(16):3783-3793. (Pubitemid 34994009)
38. Johnson DE, Lee PL, Lu J, Williams LT. Diverse forms of a receptor for acidic and basic fibroblast growth factors. Mol Cell Biol. 1990;10(9):4728-4736.
39. Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol. 2001;2(3): REVIEWS3005.
40. Schlessinger J, Mohammadi M. Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and ligand-binding promiscuity. Proc Natl Acad Sci U S A. 2004;101(4):935-940. (Pubitemid 38160562)
41. Miki T, et al. Determination of ligand-binding specificity by alternative splicing: two distinct growth factor receptors encoded by a single gene. Proc Natl Acad Sci U S A. 1992;89(1):246-250.
42. Orr-Urtreger A, et al. Developmental localization of the splicing alternatives of fibroblast growth factor receptor-2 (FGFR2). Dev Biol. 1993;158(2):475-486. (Pubitemid 23243904)
43. Ornitz DM, et al. Receptor specificity of the fibroblast growth factor family. J Biol Chem. 1996;271(25):15292-15297. (Pubitemid 26195013)
44. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2000;103(2):211-225.
45. Dailey L, Ambrosetti D, Mansukhani A, Basilico C. Mechanisms underlying differential responses to FGF signaling. Cytokine Growth Factor Rev. 2005;16(2):233-247. (Pubitemid 40616120)
46. Khavari TA, Rinn J. Ras/Erk MAPK signaling in epidermal homeostasis and neoplasia. Cell Cycle. 2007;6(23):2928-2931.
47. Shukla V, Coumoul X, Wang RH, Kim HS, Deng CX. RNA interference and inhibition of MEK-ERK signaling prevent abnormal skeletal phenotypes in a mouse model of craniosynostosis. Nat Genet. 2007;39(9):1145-1150. (Pubitemid 47340648)
48. Wang Y, et al. Abnormalities in cartilage and bone development in the Apert syndrome FGFR2(+/S252W) mouse. Development. 2005;132(15):3537-3548. (Pubitemid 41246127)
49. Wang Y, et al. Activation of p38 MAPK pathway in the skull abnormalities of Apert syndrome Fgfr2(+/P253R) mice. BMC Dev Biol. 2010;10:22.
50. Yin L, et al. A Pro253Arg mutation in fibroblast growth factor receptor 2 (Fgfr2) causes skeleton malformation mimicking human Apert syndrome by affecting both chondrogenesis and osteogenesis. Bone. 2008;42(4):631-643.
51. Holmes G, Rothschild G, Roy UB, Deng CX, Mansukhani A, Basilico C. Early onset of craniosynostosis in an Apert mouse model reveals critical features of this pathology. Dev Biol. 2009;328(2):273-284.
52. Ong SH, Hadari YR, Gotoh N, Guy GR, Schlessinger J, Lax I. Stimulation of phosphatidylinositol 3-kinase by fibroblast growth factor receptors is mediated by coordinated recruitment of multiple docking proteins. Proc Natl Acad Sci U S A. 2001;98(11):6074-6079. (Pubitemid 32488195)
53. Yong HY, Koh MS, Moon A. The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer. Expert Opin Investig Drugs. 2009;18(12):1893-1905.
54. Mayer RJ, Callahan JF. p38 MAP kinase inhibitors: a future therapy for inflammatory diseases. Drug Discov Today. 2006;3:49-54.
55. Logié A, et al. Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. Hum Mol Genet. 2005;14(9):1153-1160. (Pubitemid 40613904)
56. Wolfram JA, et al. Keratinocyte but not endothelial cell-specific overexpression of Tie2 leads to the development of psoriasis. Am J Pathol. 2009;174(4):1443-1458.
57. Meyers GA, Orlow SJ, Munro IR, Przylepa KA, Jabs EW. Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans. Nat Genet. 1995;11(4):462-464.
58. Wilkes D, et al. A recurrent mutation, ala391glu, in the transmembrane region of FGFR3 causes Crouzon syndrome and acanthosis nigricans. J Med Genet. 1996;33(9):744-748. (Pubitemid 26302485)
59. Bellus GA, et al. Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN): Phenotypic analysis of a new skeletal dysplasia caused by a Lys650Met mutation in fibroblast growth factor receptor 3. Am J Med Genet. 1999;85(1):53-65. (Pubitemid 29256805)
60. Passos-Bueno MR, Wilcox WR, Jabs EW, SertiéAL, Alonso LG, Kitoh H. Clinical spectrum of fibroblast growth factor receptor mutations. Hum Mutat. 1999;14(2):115-125. (Pubitemid 29372778)
61. Tavormina PL, et al. A novel skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a Lys650Met mutation in the fibroblast growth factor receptor 3 gene. Am J Hum Genet. 1999;64(3):722-731. (Pubitemid 30460414)
62. Melnik BC. Role of FGFR2-signaling in the pathogenesis of acne. Dermatoendocrinol. 2009;1(3):141-156.
63. Dorey K, Amaya E. FGF signalling: diverse roles during early vertebrate embryogenesis. Development. 2010;137(22):3731-3742.
64. Ford-Perriss M, Abud H, Murphy M. Fibroblast growth factors in the developing central nervous system. Clin Exp Pharmacol Physiol. 2001;28(7):493-503. (Pubitemid 32588423)
65. Suhardja A, Hoffman H. Role of growth factors and their receptors in proliferation of microvascular endothelial cells. Microsc Res Tech. 2003;60(1):70-75. (Pubitemid 36055235)
66. Degnin CR, Laederich MB, Horton WA. FGFs in endochondral skeletal development. J Cell Biochem. 2010;110(5):1046-1057.
67. Neilson KM, Friesel RE. Constitutive activation of fibroblast growth factor receptor-2 by a point mutation associated with Crouzon syndrome. J Biol Chem. 1995;270(44):26037-26040.
68. Wilkie AO, et al. Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome. Nat Genet. 1995;9(2):165-172.
69. Chen F, Degnin C, Laederich M, Horton WA, Hristova K. The A391E mutation enhances FGFR3 activation in the absence of ligand. Biochim Biophys Acta. 2011;1808(8):2045-2050.
70. Chopra P, Kanoje V, Semwal A, Ray A. Therapeutic potential of inhaled p38 mitogen-activated protein kinase inhibitors for inflammatory pulmonary diseases. Expert Opin Investig Drugs. 2008;17(10):1411-1425.
71. Efimova T. p38delta mitogen-activated protein kinase regulates skin homeostasis and tumorigenesis. Cell Cycle. 2010;9(3):498-505.
72. Hu Y, Chan E, Wang SX, Li B. Activation of p38 mitogen-activated protein kinase is required for osteoblast differentiation. Endocrinology. 2003;144(5):2068-2074. (Pubitemid 36543347)
73. Wang X, Goh CH, Li B. p38 mitogen-activated protein kinase regulates osteoblast differentiation through osterix. Endocrinology. 2007;148(4):1629- 1637. (Pubitemid 46457114)
74. Haase I, Hunzelmann N. Activation of epidermal growth factor receptor/ERK signaling correlates with suppressed differentiation in malignant acanthosis nigricans. J Invest Dermatol. 2002;118(5):891-893. (Pubitemid 34526556)
75. Torley D, Bellus GA, Munro CS. Genes growth factors and acanthosis nigricans. Br J Dermatol. 2002;147(6):1096-1101. (Pubitemid 36963014)
76. Higgins SP, Freemark M, Prose NS. Acanthosis nigricans: A practical approach to evaluation and management. Dermatol Online J. 2008;14(9):2.
77. Anderson J, Burns HD, Enriquez-Harris P, Wilkie AO, Heath JK. Apert syndrome mutations in fibroblast growth factor receptor 2 exhibit increased affinity for FGF ligand. Hum Mol Genet. 1998;7(9):1475-1483. (Pubitemid 28429929)
78. Yu K, et al. Conditional inactivation of FGF receptor 2 reveals an essential role for FGF signaling in the regulation of osteoblast function and bone growth. Development. 2003;130(13):3063-3074. (Pubitemid 36857252)
79. Hogan B, Beddington R, Constantini F, Lacy E, eds. Staining embryos for cartilage and bone. In: Manipulating the Mouse Embryo: A Laboratory Manual. Cold Spring Harbor, New York, USA: Cold Spring Harbor Laboratory Press; 1994:379.
80. Richtsmeier JT, Paik CH, Elfert PC, Cole TM 3rd, Dahlman HR. Precision, repeatability, and validation of the localization of cranial landmarks using computed tomography scans. Cleft Palate Craniofac J. 1995;32(3):217-227.
81. Corner BD, Lele S, Richtsmeier JT. Measuring precision of three-dimensional landmark data. J Quant Anthropol. 1992;3(4):347-359.
82. Lele S, Richtsmeier JT, eds. An invariant approach to statistical analysis of shapes. In: Interdisciplinary Studies In Statistics Series. London, United Kingdom; Chapman and Hall-CRC Press; 2001.
83. Wilkinson DG, eds. In Situ Hybridization: A Practical Approach. London, United Kingdom: Oxford University Press; 1992.
84. Costantini TW, et al. Role of p38 MAPK in burn-induced intestinal barrier breakdown. J Surg Res. 2009;156(1):64-69.
85. Bracht L, Caparroz-Assef SM, Magon TF, Ritter AM, Cuman RK, Bersani-Amado CA. Topical anti-inflammatory effect of hypocholesterolaemic drugs. J Pharm Pharmacol. 2011;63(7):971-975.